Data −Apr 11, 2026
Negative data — Insmed (INSM): Top QQQ Stock to Buy Now▸
high impact
Data −Apr 07, 2026
Negative data — Insmed Provides Clinical Update on Phase 2b CEDAR Study▸
high impact
Data +Apr 03, 2026
Positive data — Insmed (INSM) Is Up 10.0% After Positive ENCORE Data Position ARIKAYCE For Earlier MAC Use▸
high impact
Data +Apr 01, 2026
Positive data — Insmed: The Pipeline Is Catching Up To The Valuation▸
high impact
Data +Mar 24, 2026
Positive data — A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data▸
high impact
Data +Mar 23, 2026
Positive data — Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains▸
high impact
Data −Feb 19, 2026
Negative data — Insmed: Q4 Earnings Snapshot▸
high impact
EarningsFeb 17, 2026
FY 2025 report+9.6%positive
ReadoutFeb 12, 2026
Brensocatib — Phase 2 readout complete▸
low impact
ReadoutJan 30, 2026
Clinical data — What Insmed (INSM)'s Upcoming TPIP Data and New Analyst Coverage Mean For Shareholders▸
medium impact
ReadoutJan 29, 2026
Clinical data — Insmed TPIP Data At PVRI 2026 Tests Pulmonary Arterial Hypertension Ambitions▸
medium impact
EarningsOct 30, 2025
Q3 2025 report-5.9%negative
ReadoutOct 25, 2025
TPIP F2 — Phase 1 readout complete▸
low impact
EarningsAug 07, 2025
Q2 2025 report+11.6%positive
EarningsMay 08, 2025
Q1 2025 report+0.1%muted
EarningsFeb 18, 2025
FY 2024 report-0.4%muted
EarningsOct 31, 2024
Q3 2024 report+3.0%positive
ReadoutOct 28, 2024
Brensocatib 10 mg — Phase 3 readout complete▸
low impact
EarningsAug 08, 2024
Q2 2024 report+6.4%positive
EarningsMay 09, 2024
Q1 2024 report-3.5%negative